Characterization of Immunosuppressive Signing of Cervical Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02875990

Acronym

Xac03

Enrollment

Registered

2016-08-23

Start date

2016-09-30

Completion date

2024-09-30

Last updated

2016-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Brief summary

Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer. The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.

Interventions

BIOLOGICALBlood sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* The women presenting for initial therapeutic management of cervical cancer * Elderly patients over 18 years * Patients beneficiary of a social security scheme * Pregnant women can not participate in this study * Women known to be HIV positive will not participate in this study

Exclusion criteria

* Patients with a recurrence of a treaty cervical cancer * Patients with a history of pelvic radiotherapy * Patients unable to receive informed about the progress and objectives of the study * Patients not receiving a social security scheme * Patients who have not signed informed consent * Immunocompromised patients and pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Lack of tumor emboli histological analysis	60 months	Patients with good prognosis of cervical cancer

Countries

France

Contacts

Primary ContactXavier CARCOPINO, PU-PH

xavier.carcopino@ap-hm.fr

Backup ContactUrielle DESALBRES, Director

drci@ap-hm.fr04.91.38.27.47

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026